Sikander Ailawadhi, MD

Sikander Ailawadhi, MD discusses the positive sentiments on subcutaneous isatuximab from European regulators and patient groups.

As regulators examine the on-body injector used with isatuximab in multiple myeloma, Sikander Ailawadhi, MD, provides commentary on frequently asked questions.

Clinical trials show subcutaneous isatuximab is preferred by patients, enabling faster dosing, home treatment, and paving the way for future self-administration.

On-body injector isatuximab enables at-home myeloma treatment, cutting infusion visits, easing time and financial strain, and expanding access for rural patients.

On-body isatuximab injection matches IV results in relapsed multiple myeloma, with similar safety, drug levels, and better convenience.

This article reviews some of the concepts surrounding the diagnosis of multiple myeloma are still evolving, and are thus shaping how we see and manage multiple myeloma - hopefully moving slowly but surely toward its elusive cure.